During the past decade, Perron Institute for Neurological and Translational Science conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Perron Institute for Neurological and Translational Science" #1 sponsor was "Theravance Biopharma" with 2 trials, followed by "Alexion" with 1 trials sponsored, "Cytokinetics" with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Impel Pharmaceuticals" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Perron Institute for Neurological and Translational Science" #1 collaborator was "Deakin University" with 1 trials as a collaborator, "King's College London" with 1 trials as a collaborator, "Monash University" with 1 trials as a collaborator, "Royal Perth Hospital" with 1 trials as a collaborator and "Stichting TRICALS Foundation" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Perron Institute for Neurological and Translational Science" are "Amyotrophic Lateral Sclerosis" (3 trials), "ALS" (2 trials), "Symptomatic Neurogenic Orthostatic Hypotension" (2 trials), "FTD" (1 trials) and "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" (1 trials). Many other conditions were trialed in "Perron Institute for Neurological and Translational Science" in a lesser frequency.

Most popular intervention types in "Perron Institute for Neurological and Translational Science" are "Drug" (10 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "ampreloxetine" (2 trials), "Dolutegravir, Abacavir and Lamivudine" (1 trials), "Eplontersen" (1 trials) and "Inotersen" (1 trials). Other intervention names were less common.

The vast majority of trials in "Perron Institute for Neurological and Translational Science" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Perron Institute for Neurological and Translational Science". 1 are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Perron Institute for Neurological and Translational Science, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Perron Institute for Neurological and Translational Science, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".